| Identification | More | [Name]
Nisoldipine | [CAS]
63675-72-9 | [Synonyms]
1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLIC ACID METHYL 2-METHYLPROPYL ESTER
BAY K 5552
BAYMYCARD
NISOLDIPINE
NISOLIDIPINE
NORVASC
SYSCOR
ZADIPINA
5-pyridinedicarboxylicacid,1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-met
hyl2-methylpropylester
Nisoldipin
ISOBUTYL METHYL (-1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Baymycard, Norvasc, Syscor, Zadipina, 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic Acid Methyl 2-methylpropyl Ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester (9CI)
Nisocor
Sular
Nisoldipine-d6
2，6-Dimethyl-4-(2-nitmphenyl)-1，4-dihydro-3，5-pyridinedicarboxylic acid methyl 2-methylpropyl ester
Syseor
1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-isobutyl ester | [EINECS(EC#)]
264-407-7 | [Molecular Formula]
C20H24N2O6 | [MDL Number]
MFCD00478055 | [Molecular Weight]
388.41 | [MOL File]
63675-72-9.mol |
| Chemical Properties | Back Directory | [Appearance]
Light Tan Crystals | [Melting point ]
147-148°C | [Boiling point ]
503.3±50.0 °C(Predicted) | [density ]
1.205±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: >10mg/mL | [form ]
powder | [pka]
2.67±0.70(Predicted) | [color ]
yellow | [Usage]
Dihydropyridine calcium channel blocker. Antihypertensive and antianginal | [Merck ]
14,6565 | [InChIKey]
VKQFCGNPDRICFG-UHFFFAOYSA-N | [CAS DataBase Reference]
63675-72-9(CAS DataBase Reference) | [NIST Chemistry Reference]
Nisoldipine(63675-72-9) |
| Hazard Information | Back Directory | [Description]
Nisoldipine D4 is another long-acting dihydropyridine calcium channel blocker effective in the treatment of hypertension and angina pectoris. It is reported to have little or no cardiodepressive activity and to be more effective than nifedipine in reducing blood pressure in hypertensives. Nisoldipine has also been shown to be effective in the management of congestive heart failure. Reduction in dosage is necessary in patients with hepatic, but not renal impairment.
| [Chemical Properties]
Nisoldipine D4 is Light Tan Crystals
| [Originator]
Bayer AG (Germany) | [Uses]
Dihydropyridine calcium channel blocker. Antihypertensive and antianginal | [Uses]
Labeled Nisoldipine, intended for use as an internal standard for the quantification of Nisoldipine by GC- or LC-mass spectrometry. | [Uses]
urease inhibitor | [Definition]
ChEBI: A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate,
calcium channel blocker, is used in the treatment of hypertension and angina pectoris. | [Manufacturing Process]
Boiling a solution of 12.7 g of 2'-nitrobenzylideneacetoacetic acid methyl ester
and 7.1 g of β-amino-crotonic acid isopropyl ester in 50 ml of methanol for 10
hours yielded 2,6-dimethyl-4-(2'-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylic acid 3-methyl ester-5-isopropyl ester of melting point 174°C
(from ethanol). Yield 48% of theory. | [Brand name]
Sular (Sciele);Baymycard. | [Therapeutic Function]
Coronary vasodilator | [General Description]
In vitro studies show that the effects ofnisoldipine, 1,4-dihydro-2, 6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylic acid methyl 2-methylpropyl ester(Sular), on contractile processes are selective, with greaterpotency on vascular smooth muscle than on cardiac muscle.
Nisoldipine is highly metabolized, with five majormetabolites identified. As with most of the dihydropyridines,the cytochrome P450 (CYP) 3A4 isozyme is mainlyresponsible for the metabolism of nisoldipine. The majorbiotransformation pathway appears to involve the hydroxylationof the isobutyl ester side chain. This particular metabolitehas approximately 10% of the activity of the parentcompound. | [Biochem/physiol Actions]
L-type (CaV1.2) calcium channel blocker; dihydropyridine-type calcium channel blocker with selectivity for smooth muscle (CaV1.2b) over cardiac muscle (CaV1.2a). Arterial vasodilator and antihypertensive agent. | [References]
[1] Patent: WO2004/2958, 2004, A1. Location in patent: Page 4-5 |
|
|